Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights

Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer

Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information

Basic Trial Information

Phase
Type
Status
Age
Sponsor
Protocol IDs

Phase II

Treatment

Active

18 and over

Other

OSU-0494
NCT00201864

Trial Description

Summary

The purpose of this trial is to evaluate time to progression in women with hormone responsive advanced breast cancer treated with a combination of exemestane and fulvestrant.

Eligibility Criteria

Inclusion Criteria:

Must ER &/or PR+;

Postmenopausal;

No chemotherapy for metastatic

No prior Exemestane or Fulvestrant

Trial Contact Information

Trial Lead Organizations/Sponsors

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center

Pfizer Incorporated

Charles Shapiro

Principal Investigator

Ohio State University Clinical Trial Matching Service		Ph: 866-627-7616
		Email: osu@emergingmed.com

Trial Sites

U.S.A.

Ohio

Columbus

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00201864
Information obtained from ClinicalTrials.gov on July 16, 2008

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.